TG Therapeutics | TGTX - Debt


TG Therapeutics reported $245.34M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 54.59B 1.62B Sep/2025
Ardelyx USD 207.61M 968K Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.29B 1.7M Dec/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Curis USD 0 0 Jun/2022
Gilead Sciences USD 24.94B 5M Sep/2025
Infinity Pharmaceuticals USD 0 0 Jun/2022
J&J USD 45.8B 4.97B Sep/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Novartis USD 32.64B 1.37B Jun/2025
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025
Verastem USD 66.79M 26.7M Sep/2024
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025